Intravenous Immunoglobulin Market Growth Driven by Rising Immunodeficiency Diseases and Aging Population.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Intravenous Immunoglobulin Market Size, Share & Trends Analysis Report By Application (Hypogammaglobulinemia, CIDP, Congenital AIDS), By Distribution Channel (hospital pharmacies, speciality pharmacies), Region, Market Outlook And Industry Analysis 2031"

The global Intravenous Immunoglobulin market is estimated to reach over USD 21.22 billion by 2031, exhibiting a CAGR of 6.60% during the forecast period.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/1874

Immunoglobulins are made from a large human plasma pool obtained from at least 100 donors. The intramuscular route of administration is a traditional procedure that is no longer favoured due to its unpleasantness. In recent years, intravenous immunoglobulin has been a lifeline for people with impaired immune systems. The increasing incidences of target disorders, such as primary immunodeficiency disorders, are expected to expand the market. The rising frequency of immunodeficiency illnesses, technological breakthroughs and investments, rising acceptance of immunoglobulin therapy, and an ageing population will likely fuel market revenue growth over the forecast period. IVIG is a sterile, concentrated set of antibodies from healthy persons injected directly into a vein. It is used to treat immune system disorders or to increase immunological response. The expense of diagnosing and treating demyelinating illness is exceptionally high. The rising cost of IVIG therapy is expected to be a significant impediment to market growth. Immunoglobulin infusions are typically given every 3 to 4 weeks, and the treatment is repeated 12-16 times per year. Depending on the severity of the patient's condition, the anticipated expense of IVIG is USD 73.89 per gram, with a total cost of USD 10,000.

List of Prominent Players in the Intravenous Immunoglobulin Market:
• Biotest AG
• Baxter International Inc.
• Octapharma AG
• LFB Biotechnologies
• Grifols SA
• CSL Behring
• China Biologics Products Inc.
• Kedrion Biopharma
• BDI Pharma Inc

Market Dynamics:
Drivers-
The rise in the geriatric population, the increased acceptance of immunoglobulin treatment, and the growing prevalence of immunodeficiency diseases and bleeding disorders are all key drivers driving the market growth. With new product launches and approvals, the immunoglobulin market is expected to develop in the future. IVIG therapies are in high demand for treating acquired and primary immunodeficiency illnesses since they are the most effective and only viable therapy option. Furthermore, inactive lifestyle practices, such as eating saturated fats, salt, and sweets, as well as a deficiency of physical exercise and excessive alcohol use, have contributed to an increase in the prevalence of these diseases

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02

Challenges:
The high cost of intravenous immunoglobulin therapy will limit their usage, limiting market revenue growth to some extent over the projection period. The supply chain may be a source of concern due to a scarcity of raw materials, and various countries' severe regulatory policies would stifle business expansion. Immunoglobulin therapy, as one of the most technologically advanced therapies, is quite expensive. One of the major problems impeding the growth of the IVIG market is the high cost of medicines. Furthermore, plasma collection, purification, and scarcity are all quite expensive due to modern technologies and the creation of appropriate healthcare infrastructure. As a result, the issue of the plasma supply chain is prevalent in most parts of the world.

Regional Trends:
The North America Intravenous Immunoglobulin market is expected to register a major market share in revenue and is projected to grow at a high CAGR shortly. The country's sophisticated and well-structured healthcare system, a growing emphasis on research and development, and the strong presence of industry players drive market expansion. Besides, Asia Pacific had a considerable share in the market, Increasing awareness and forthcoming opportunities for the use of immunoglobulin-based medicines to treat primary immunological deficiencies in conjunction with an ageing population.

Recent Developments:
• In March 2022, Sanofi and Seagen Inc. agreed to work exclusively to discover, develop, and commercialize antibody-drug conjugates (ADCs) targeting up to three cancer targets. Sanofi's unique monoclonal antibody (mAb) technology and Seagen's patented ADC technology will be used in the cooperation.
• In January 2022, Argenx SE, a global immunology company dedicated to improving the lives of people suffering from severe autoimmune diseases, announced that Japan's Ministry of Health, Labour, and Welfare (MHLW) had approved VYVGART (efgartigimod alfa) intravenous infusion for the therapy of adult patients with generalized myasthenia gravis (gMG) who have not answered adequately to steroids or non-steroidal immunosuppressive therapies (ISTs).

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/1874

Segmentation of Intravenous Immunoglobulin Market-
By Application-
• Hypogammaglobulinemia
• CIPD
• Immunodeficiency Diseases
• Congenital AIDS
• Chronic Lymphocytic Leukemia
• Myasthenia Gravis
• Multifocal Motor Neuropathy
• ITP
• Kawasaki Disease
• Guillain-barre Syndrome
• Others
By Distribution Channel-
• Hospital Pharmacy
• Specialty Pharmacy
• Others
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/1874

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.